Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Zvi Steinberg who wrote (384)	1/2/1999 10:12:00 PM
From: DinoRia	Read Replies (1) \| Respond to of 1386

Hi Zvi, I thank my friend Pillx, helping me on this thread. Just want you to know that I'm the one in Belgium starting it all, and I hope you will help me all. Money will flow in. Only last day my friends bought almost 70.000 shares Regards, Dinoria Just look there for Dinoria and try to translate !

To: Zvi Steinberg who wrote (384)	1/3/1999 10:23:00 AM
From: crysball	Read Replies (1) \| Respond to of 1386

Zvi, Ariealla, et al, A very insightful and important post by Pillx. If HU211 does, in fact, meet FDA fast track criteria, and if, as Pillx suggests, it allows rolling surrogate endpoints [with all the associated implications for a smaller/faster and less costly PH3], then fast track qualification for HU211 would also have significant implications for PARS ability to attract a strategic partner, since it lowers the time/cost/risk aspects. P.S. Pillx's prior scientific/medical remarks have always been right on the money.........am merely looking for additional confirmation, as interpreting the FDA regs can be very convoluted. Assuming Pillx is correct extending the logic to the search for a strategic partner seems a natural........and perhaps a means for PARS to secure an even better negotiating position [royalty %, etc]